UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis

BMC neurology, 2020-07, Vol.20 (1), p.281-281, Article 281

2020

Volltextzugriff (PDF)

Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data

BMC neurology, 2019-10, Vol.19 (1), p.258-258, Article 258

2019

Volltextzugriff (PDF)

Associations of sNfL with clinico‐radiological measures in a large MS population

Annals of clinical and translational neurology, 2023-01, Vol.10 (1), p.84-97

2023

Volltextzugriff (PDF)

Thalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting multiple sclerosis

NeuroImage clinical, 2024-01, Vol.42, p.103609, Article 103609

2024

Volltextzugriff (PDF)

Examining Trait Mindfulness, Emotion Dysregulation, and Quality of Life in Multiple Sclerosis

Health psychology, 2015-11, Vol.34 (11), p.1107-1115

2015

Volltextzugriff (PDF)

Effects of 4-Week Mindfulness Training Versus Adaptive Cognitive Training on Processing Speed and Working Memory in Multiple Sclerosis

Neuropsychology, 2020-07, Vol.34 (5), p.591-604

2020

Volltextzugriff (PDF)

A promising cognitive screener in multiple sclerosis: The NIH toolbox cognition battery concords with gold standard neuropsychological measures

Multiple sclerosis, 2022-10, Vol.28 (11), p.1762-1772

2022

Volltextzugriff (PDF)

Employing Connectome-Based Models to Predict Working Memory in Multiple Sclerosis

Brain connectivity, 2022-08, Vol.12 (6), p.502-514

2022

Volltextzugriff (PDF)

Trait mindfulness, emotion dysregulation, and depression in individuals with multiple sclerosis

Multiple sclerosis and related disorders, 2022-03, Vol.59, p.103651-103651, Article 103651

2022

Volltextzugriff (PDF)

TRACking health behavior in people with multiple sclerosis: Effects of a randomized trial on physical activity and working memory

Rehabilitation psychology, 2024-08

2024

Volltextzugriff (PDF)

Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis

Neurology, 2023-12, Vol.101 (23), p.e2448

2023

Volltextzugriff (PDF)

De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate

Advances in therapy, 2024-08, Vol.41 (8), p.3059-3075

2024

Volltextzugriff (PDF)

Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic

Neurology : neuroimmunology & neuroinflammation, 2021-11, Vol.8 (6)

2021

Volltextzugriff (PDF)

Impact of Mindfulness Training on Emotion Regulation in Multiple Sclerosis: Secondary Analysis of a Pilot Randomized Controlled Trial

Rehabilitation psychology, 2022-11, Vol.67 (4), p.449-460

2022

Volltextzugriff (PDF)

Accelerometry measures of physical activity and sedentary behavior: Associations with cognitive functioning in MS

Multiple sclerosis and related disorders, 2023-11, Vol.79, p.104963-104963, Article 104963

2023

Volltextzugriff (PDF)

Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab

Multiple sclerosis and related disorders, 2022-07, Vol.63, p.103921-103921, Article 103921

2022

Volltextzugriff (PDF)

Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era

Multiple sclerosis and related disorders, 2021-04, Vol.49, p.102715-102715, Article 102715

2021

Volltextzugriff (PDF)

Static and group-based trajectory analyses of factors associated with non-adherence in patients with multiple sclerosis newly-initiating once- or twice-daily oral disease-modifying therapy

Multiple sclerosis journal - experimental, translational and clinical, 2022-04, Vol.8 (2), p.20552173221101150-20552173221101150

2022

Volltextzugriff (PDF)

Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study

Multiple sclerosis journal - experimental, translational and clinical, 2022-10, Vol.8 (4), p.20552173221135888-20552173221135888

2022

Volltextzugriff (PDF)

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab

JAMA neurology, 2013-03, Vol.70 (3), p.398

2013

Volltextzugriff (PDF)

Concise Review: Modeling Multiple Sclerosis With Stem Cell Biological Platforms: Toward Functional Validation of Cellular and Molecular Phenotypes in Inflammation‐Induced Neurodegeneration

Stem cells translational medicine, 2015-03, Vol.4 (3), p.252-260

2015

Volltextzugriff (PDF)

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Lancet neurology, 2022-07, Vol.21 (7), p.608-619

2022

Volltextzugriff (PDF)

Reproductive issues in women with multiple sclerosis: ethical considerations

Continuum (Minneapolis, Minn.), 2014-02, Vol.20 (1 Neurology of Pregnancy), p.177-180

2014

Volltextzugriff (PDF)

Multiple sclerosis: Five new things

Neurology. Clinical practice, 2013-10, Vol.3 (5), p.404-412

2013

Volltextzugriff (PDF)

1 – 25 von 1.558

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.411)
Mit Volltextzugriff
(1.324)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(973)
Life Sciences & Biomedicine
(792)
Humans
(555)
Female
(298)
Male
(279)
Animals
(194)
Biological And Medical Sciences
(163)
Adult
(160)
Middle Aged
(154)
Aged
(120)
Physical Sciences
(115)
Medical Sciences
(114)
Mice
(101)
Neurosciences & Neurology
(99)
Science & Technology - Other Topics
(94)
Multidisciplinary Sciences
(88)
Risk Factors
(85)
Biochemistry & Molecular Biology
(84)
Oncology
(75)
Fundamental And Applied Biological Sciences. Psychology
(70)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(832)
MEDLINE
(723)
Ingenta.com
(585)
Journals@Ovid Complete
(446)
Standalone journals
(400)
IngentaConnect Journals
(277)
Elsevier ScienceDirect Journals Complete
(213)
Wiley Online Library All Journals
(179)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(144)
Wiley Online Library
(124)
Nature_系列刊
(110)
JSTOR
(77)
Springer Nature - Complete Springer Journals
(68)
Nexis Uni
(67)
Oxford Journals
(61)
eBooks on EBSCOhost
(56)
Ebook Central Perpetual and DDA
(55)
Taylor & Francis Journals
(47)
Taylor & Francis:Master (3349 titles)
(46)
Oxford Journals 2020 Medicine
(45)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(62)
Plos One
(40)
Neurology
(35)
Nature Communications
(21)
The Astrophysical Journal
(20)
Nature Genetics
(19)
Atmospheric Chemistry And Physics
(15)
Proceedings Of The National Academy Of Sciences - Pnas
(14)
The Journal Of Biological Chemistry
(14)
The Journal Of Immunology
(14)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis

Burden of relapsing-remitting multiple sclerosis on workers in the US: a cross-sectional analysis of survey data

Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)

Associations of sNfL with clinico‐radiological measures in a large MS population

Thalamic atrophy and dysconnectivity are associated with cognitive impairment in a multi-center, clinical routine, real-word study of people with relapsing-remitting multiple sclerosis

Examining Trait Mindfulness, Emotion Dysregulation, and Quality of Life in Multiple Sclerosis

Effects of 4-Week Mindfulness Training Versus Adaptive Cognitive Training on Processing Speed and Working Memory in Multiple Sclerosis

A promising cognitive screener in multiple sclerosis: The NIH toolbox cognition battery concords with gold standard neuropsychological measures

Employing Connectome-Based Models to Predict Working Memory in Multiple Sclerosis

Trait mindfulness, emotion dysregulation, and depression in individuals with multiple sclerosis

TRACking health behavior in people with multiple sclerosis: Effects of a randomized trial on physical activity and working memory

Agreement Between Published Reference Resources for Neurofilament Light Chain Levels in People With Multiple Sclerosis

De-escalation of Disease-Modifying Therapy for People with Multiple Sclerosis Due to Safety Considerations: Characterizing 1-Year Outcomes in 25 People Who Switched from Ocrelizumab to Diroximel Fumarate

Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic

Impact of Mindfulness Training on Emotion Regulation in Multiple Sclerosis: Secondary Analysis of a Pilot Randomized Controlled Trial

Accelerometry measures of physical activity and sedentary behavior: Associations with cognitive functioning in MS

Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab

Pandemic forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era

Static and group-based trajectory analyses of factors associated with non-adherence in patients with multiple sclerosis newly-initiating once- or twice-daily oral disease-modifying therapy

Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study

Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab

Concise Review: Modeling Multiple Sclerosis With Stem Cell Biological Platforms: Toward Functional Validation of Cellular and Molecular Phenotypes in Inflammation‐Induced Neurodegeneration

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

Reproductive issues in women with multiple sclerosis: ethical considerations

Multiple sclerosis: Five new things

Suchergebnisse filtern